0.028378 0.000000 0.000000 0.000000 0.028378 0.000000 0.000000 0.000000 0.009556 0.00000 0.00000 0.00000 Yadav, M.K. Leman, L.J. Stout, C.D. Ghadiri, M.R. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 16 90.00 90.00 90.00 35.238 35.238 104.647 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking H2 O 18.015 WATER non-polymer C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Biochemistry BICHAW 0033 0006-2960 44 9723 10.1021/BI050742A 16008357 Structure-Based Engineering of Internal Cavities in Coiled-Coil Peptides 2005 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 93.0 1 CONFOCAL 2004-05-29 NI FILTER SINGLE WAVELENGTH M x-ray 1 1.5418 1.0 1.5418 ROTATING ANODE RIGAKU RU200 PEPTIDE REACTED WITH IODOACETIMIDE TO YEILD THIOETHER FROM CYSTEINE. NOTE SHIFT IN TYROSINE POSITION FROM PDB ENTRY 1VZL 4020.829 GENERAL CONTROL PROTEIN GCN4 YES 2 syn polymer 18.015 water 2 nat water AMINO ACID BIOSYNTHESIS REGULATORY PROTEIN, PLI E20C ACETIMIDE no no RMKQIEDKLEEILSKLYHICNELARIKKLLGER RMKQIEDKLEEILSKLYHICNELARIKKLLGER A,B polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n 1 2 38.9 VAPOR DIFFUSION, HANGING DROP 10.00 HANGING DROP, 1UL OF 1MG/ML PEPTIDE IN WATER, 1UL 100MM CAPS, 30% PEG 400, PH 10.5. database_PDB_rev database_PDB_rev_record exptl_crystal_grow pdbx_database_proc pdbx_database_status repository Initial release Version format compliance Version format compliance Data collection Experimental preparation Other 1 0 2004-09-24 1 1 2011-05-08 1 2 2011-07-13 1 3 2019-05-08 _exptl_crystal_grow.method _pdbx_database_status.recvd_author_approval HELIX CAPPING IN THE GCN4 LEUCINE ZIPPER GCN4 LEUCINE ZIPPER COMPLEXED WITH SPECIFIC ATF/CREB SITE DEOXYRIBONUCLEIC ACID ATOMIC STRUCTURE OF THE ECTODOMAIN FROM HIV -1 GP41 THE STRUCTURE OF AN HIV-1 SPECIFIC CELL ENTRY INHIBITOR INCOMPLEX WITH THE HIV-1 GP41 TRIMERIC CORE GCN4 LEUCINE ZIPPER CORE MUTANT P-LI GCN4 LEUCINE ZIPPER CORE MUTANT P-LI HUMAN VIMENTIN COIL 2B FRAGMENT LINKED TO GCN4 LEUCINE ZIPPER (Z2B) CRYSTAL STRUCTURE OF C14LINKMID/IQN17: A CROSS-LINKED INHIBITOR OF HIV-1 ENTRY BOUND TO THE GP41 HYDROPHOBIC POCKET GLYTM1BZIP: A CHIMERIC PEPTIDE MODEL OF THE N-TERMINUS OF ARAT SHORT ALPHA TROPOMYOSIN WITH THE N-TERMINUS ENCODED BYEXON 1B COILED COIL TRIMER GCN4-PVLS SER AT BURIED D POSITION GCN4-PVLT COILED-COIL TRIMER WITH THREONINE AT THE D(12)POSITION GCN4-PVTL COILED-COIL TRIMER WITH THREONINE AT THE A(16)POSITION GCN4-PVSL COILED-COIL TRIMER WITH SERINE AT THE A(16)POSITION CRYSTAL STRUCTURE OF THE C-TERMINAL REGION OF STRIATEDMUSCLE ALPHA-TROPOMYOSIN AT 2.7 ANGSTROM RESOLUTION PLACEMENT OF THE STRUCTURAL PROTEINS IN SINDBIS VIRUS CRYSTAL STRUCTURE OF A ZIF23-GCN4 CHIMERA BOUND TO DNA VISUALIZING AN UNSTABLE COILED COIL: THE CRYSTAL STRUCTUREOF AN N-TERMINAL SEGMENT OF THE SCALLOP MYOSIN ROD CRYSTAL STRUCTURE OF GCN4-PIQ, A TRIMERIC COILED COIL WITH BURIED POLAR RESIDUES GCN4-LEUCINE ZIPPER CORE MUTANT AS N16A TRIGONAL AUTOMATICSOLUTION ANTIPARALLEL TRIMER OF GCN4-LEUCINE ZIPPER CORE MUTANT ASN16A TETRAGONAL AUTOMATIC SOLUTION ANTIPARALLEL TRIMER OF GCN4-LEUCINE ZIPPER CORE MUTANT ASN16A TRIGONAL FORM ANTIPARALLEL TRIMER OF GCN4-LEUCINE ZIPPER CORE MUTANT ASN16A TETRAGONAL FORM GCN4-LEUCINE ZIPPER CORE MUTANT AS N16A COMPLEXED WITH BENZENE TMZIP: A CHIMERIC PEPTIDE MODEL OF THE N- TERMINUS OF ALPHA TROPOMYOSIN, NMR, 15 STRUCTURES CRYSTAL STRUCTURE OF B562RIL, A REDESIGNED FOUR HELIX BUNDLE STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES AN ANTI-PARALLEL FOUR HELIX BUNDLE MUTANT PLI-E20C GCN4 (BASIC REGION, LEUCINE ZIPPER) COMPLEX WITH AP-1 DEOXYRIBONUCLEIC ACID GCN4-LEUCINE ZIPPER CORE MUTANT ASN16ABA IN THE DIMERIC STATE GCN4-LEUCINE ZIPPER CORE MUTANT ASN16ABA IN THE TRIMERIC STATE GCN4-LEUCINE ZIPPER CORE MUTANT ASN16LYS IN THE DIMERIC STATE GCN4-LEUCINE ZIPPER CORE MUTANT ASN16GLN IN THE DIMERIC STATE GCN4-LEUCINE ZIPPER CORE MUTANT ASN16GLN IN THE TRIMERIC STATE LEUCINE ZIPPER MONOMER (NMR, 20 STRUCTURES) GCN4 BASIC DOMAIN, LEUCINE ZIPPER COMPLEXED WITH ATF/CREB SITE DEOXYRIBONUCLEIC ACID GCN4 LEUCINE ZIPPER AN ANTI-PARALLEL FOUR HELIX BUNDLE. AN ANTI-PARALLEL FOUR HELIX BUNDLE AN ANTI-PARALLEL FOUR HELIX BUNDLE ABA DOES NOT AFFECT TOPOLOGY OF PLI. AN ANTI-PARALLEL TO PARALLEL SWITCH. PDBE Y PDBE 2004-08-06 REL HOH water 4932 BAKER'S YEAST SACCHAROMYCES CEREVISIAE sample CHAIN A, B ENGINEERED MUTATION GLU 268 CYS THE N-TERMINUS OF THIS PEPTIDE IS ACETYLATED. HOH 2001 2 HOH HOH 2001 A HOH 2001 2 HOH HOH 2001 B ARG 1 n 1 ARG 1 A MET 2 n 2 MET 2 A LYS 3 n 3 LYS 3 A GLN 4 n 4 GLN 4 A ILE 5 n 5 ILE 5 A GLU 6 n 6 GLU 6 A ASP 7 n 7 ASP 7 A LYS 8 n 8 LYS 8 A LEU 9 n 9 LEU 9 A GLU 10 n 10 GLU 10 A GLU 11 n 11 GLU 11 A ILE 12 n 12 ILE 12 A LEU 13 n 13 LEU 13 A SER 14 n 14 SER 14 A LYS 15 n 15 LYS 15 A LEU 16 n 16 LEU 16 A TYR 17 n 17 TYR 17 A HIS 18 n 18 HIS 18 A ILE 19 n 19 ILE 19 A CYS 20 n 20 CYS 20 A ASN 21 n 21 ASN 21 A GLU 22 n 22 GLU 22 A LEU 23 n 23 LEU 23 A ALA 24 n 24 ALA 24 A ARG 25 n 25 ARG 25 A ILE 26 n 26 ILE 26 A LYS 27 n 27 LYS 27 A LYS 28 n 28 LYS 28 A LEU 29 n 29 LEU 29 A LEU 30 n 30 LEU 30 A GLY 31 n 31 GLY 31 A GLU 32 n 32 GLU 32 A n 33 33 A ARG 1 n 1 ARG 1 B MET 2 n 2 MET 2 B LYS 3 n 3 LYS 3 B GLN 4 n 4 GLN 4 B ILE 5 n 5 ILE 5 B GLU 6 n 6 GLU 6 B ASP 7 n 7 ASP 7 B LYS 8 n 8 LYS 8 B LEU 9 n 9 LEU 9 B GLU 10 n 10 GLU 10 B GLU 11 n 11 GLU 11 B ILE 12 n 12 ILE 12 B LEU 13 n 13 LEU 13 B SER 14 n 14 SER 14 B LYS 15 n 15 LYS 15 B LEU 16 n 16 LEU 16 B TYR 17 n 17 TYR 17 B HIS 18 n 18 HIS 18 B ILE 19 n 19 ILE 19 B CYS 20 n 20 CYS 20 B ASN 21 n 21 ASN 21 B GLU 22 n 22 GLU 22 B LEU 23 n 23 LEU 23 B ALA 24 n 24 ALA 24 B ARG 25 n 25 ARG 25 B ILE 26 n 26 ILE 26 B LYS 27 n 27 LYS 27 B LYS 28 n 28 LYS 28 B LEU 29 n 29 LEU 29 B LEU 30 n 30 LEU 30 B GLY 31 n 31 GLY 31 B GLU 32 n 32 GLU 32 B ARG 33 n 33 ARG 33 B author_and_software_defined_assembly PISA 4 tetrameric 5550 -85.99 7120 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 -1.0000000000 0.0000000000 0.0000000000 0.0000000000 -1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 2_765 -x+2,-y+1,z crystal symmetry operation 70.4760000000 35.2380000000 0.0000000000 1 A N ARG 1 A N ARG 1 1 Y 1 A CA ARG 1 A CA ARG 1 1 Y 1 A CB ARG 1 A CB ARG 1 1 Y 1 A CG ARG 1 A CG ARG 1 1 Y 1 A CD ARG 1 A CD ARG 1 1 Y 1 A NE ARG 1 A NE ARG 1 1 Y 1 A CZ ARG 1 A CZ ARG 1 1 Y 1 A NH1 ARG 1 A NH1 ARG 1 1 Y 1 A NH2 ARG 1 A NH2 ARG 1 1 Y 1 A CD LYS 3 A CD LYS 3 1 Y 1 A CE LYS 3 A CE LYS 3 1 Y 1 A NZ LYS 3 A NZ LYS 3 1 Y 1 A CG GLN 4 A CG GLN 4 1 Y 1 A CD GLN 4 A CD GLN 4 1 Y 1 A OE1 GLN 4 A OE1 GLN 4 1 Y 1 A NE2 GLN 4 A NE2 GLN 4 1 Y 1 A CG GLU 6 A CG GLU 6 1 Y 1 A CD GLU 6 A CD GLU 6 1 Y 1 A OE1 GLU 6 A OE1 GLU 6 1 Y 1 A OE2 GLU 6 A OE2 GLU 6 1 Y 1 A CE LYS 8 A CE LYS 8 1 Y 1 A NZ LYS 8 A NZ LYS 8 1 Y 1 A CD GLU 22 A CD GLU 22 1 Y 1 A OE1 GLU 22 A OE1 GLU 22 1 Y 1 A OE2 GLU 22 A OE2 GLU 22 1 Y 1 B CD ARG 1 B CD ARG 1 1 Y 1 B NE ARG 1 B NE ARG 1 1 Y 1 B CZ ARG 1 B CZ ARG 1 1 Y 1 B NH1 ARG 1 B NH1 ARG 1 1 Y 1 B NH2 ARG 1 B NH2 ARG 1 1 Y 1 B CG GLN 4 B CG GLN 4 1 Y 1 B CD GLN 4 B CD GLN 4 1 Y 1 B OE1 GLN 4 B OE1 GLN 4 1 Y 1 B NE2 GLN 4 B NE2 GLN 4 1 Y 1 B CD GLU 6 B CD GLU 6 1 Y 1 B OE1 GLU 6 B OE1 GLU 6 1 Y 1 B OE2 GLU 6 B OE2 GLU 6 1 Y 1 B CD GLU 10 B CD GLU 10 1 Y 1 B OE1 GLU 10 B OE1 GLU 10 1 Y 1 B OE2 GLU 10 B OE2 GLU 10 1 Y 1 B CD ARG 25 B CD ARG 25 1 Y 1 B NE ARG 25 B NE ARG 25 1 Y 1 B CZ ARG 25 B CZ ARG 25 1 Y 1 B NH1 ARG 25 B NH1 ARG 25 1 Y 1 B NH2 ARG 25 B NH2 ARG 25 1 Y 1 B CG LYS 28 B CG LYS 28 1 Y 1 B CD LYS 28 B CD LYS 28 1 Y 1 B CE LYS 28 B CE LYS 28 1 Y 1 B NZ LYS 28 B NZ LYS 28 1 Y 1 B CB ARG 33 B CB ARG 33 1 Y 1 B CG ARG 33 B CG ARG 33 1 Y 1 B CD ARG 33 B CD ARG 33 1 Y 1 B NE ARG 33 B NE ARG 33 1 Y 1 B CZ ARG 33 B CZ ARG 33 1 Y 1 B NH1 ARG 33 B NH1 ARG 33 1 Y 1 B NH2 ARG 33 B NH2 ARG 33 1 Y 1 A ARG 33 A ARG 33 1 Y 40.43 1.16000 0.00000 0.00000 1.16000 0.00000 -2.32000 0.881 0.853 HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS. 0.337 0.304 0.305 2.16 51.99 176 3754 4.500 99.4 6.182 0.166 RANDOM 1 THROUGHOUT MOLECULAR REPLACEMENT 0.351 0.269 0.80 0.80 1.40 MAXIMUM LIKELIHOOD BABINET MODEL WITH MASK 2.16 51.99 2 493 0 0 491 0.018 0.021 493 0.002 0.020 494 1.526 2.026 655 0.876 3.000 1145 4.729 5.000 62 0.068 0.200 81 0.006 0.020 510 0.004 0.020 79 0.209 0.200 154 0.218 0.200 505 0.194 0.200 470 0.285 0.200 3 0.205 0.200 11 0.286 0.200 34 0.020 0.200 1 0.891 1.500 317 1.655 2.000 501 2.437 3.000 176 4.093 4.500 154 0.2820 0.2290 2.22 10 268 20 2.160 34.880 1W5G 3960 2.000 0.05000 1 17.3000 5.370 100.0 0.22000 2.16 2.24 6.500 1 5.01 97.6 refinement REFMAC 5.1.24 data reduction CrystalClear (MSC/RIGAKU) data scaling CrystalClear (MSC/RIGAKU) phasing MOLREP GENERAL CONTROL PROTEIN GCN4 An anti-parallel four helix bundle (acetimide modification). 1 N N 1 N N 2 N N 2 N N A MET 2 A MET 2 HELX_P A GLU 32 A GLU 32 1 1 31 B ARG 1 B ARG 1 HELX_P B ARG 33 B ARG 33 1 2 33 STRUCTURAL PROTEIN STRUCTURAL PROTEIN, FOUR HELIX BUNDLE, ANTIPARALLEL FOUR HELIX BUNDLE GCN4_YEAST UNP 1 P03069 249 281 1W5G 1 33 P03069 A 1 1 33 249 281 1W5G 1 33 P03069 B 1 1 33 1 LEU conflict ILE 5 1W5G A P03069 UNP 253 5 1 LEU conflict ILE 12 1W5G A P03069 UNP 260 12 1 ASN conflict LEU 16 1W5G A P03069 UNP 264 16 1 LEU conflict ILE 19 1W5G A P03069 UNP 267 19 1 GLU engineered mutation CYS 20 1W5G A P03069 UNP 268 20 1 VAL conflict LEU 23 1W5G A P03069 UNP 271 23 1 LEU conflict ILE 26 1W5G A P03069 UNP 274 26 1 VAL conflict LEU 30 1W5G A P03069 UNP 278 30 2 LEU conflict ILE 5 1W5G B P03069 UNP 253 5 2 LEU conflict ILE 12 1W5G B P03069 UNP 260 12 2 ASN conflict LEU 16 1W5G B P03069 UNP 264 16 2 LEU conflict ILE 19 1W5G B P03069 UNP 267 19 2 GLU engineered mutation CYS 20 1W5G B P03069 UNP 268 20 2 VAL conflict LEU 23 1W5G B P03069 UNP 271 23 2 LEU conflict ILE 26 1W5G B P03069 UNP 274 26 2 VAL conflict LEU 30 1W5G B P03069 UNP 278 30 94 P 42 21 2